Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-06
1998-12-22
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, 514 21, A61K 3818
Patent
active
058519890
ABSTRACT:
The invention provides a method for extending the plasma half-life of heparin-binding proteins by coadministering such proteins with a therapeutically acceptable compound capable of inhibiting their binding to a low affinity heparin-like binding site on the surface of cells. In one embodiment of the invention, the heparin-binding protein is a growth factor or selectin. The binding inhibitory compound can, for example, be a purified native heparin preparation, a heparin fragment, or another polyanionic compound, such as dextran sulfate, heparan sulfate, pentosan sulfate, or hyaluronate.
REFERENCES:
patent: 4456550 (1984-06-01), Dvorak et al.
patent: 4844895 (1989-07-01), Thorbecke et al.
patent: 4889808 (1989-12-01), Rappaport
patent: 5057494 (1991-10-01), Sheffield
patent: 5110604 (1992-05-01), Chu et al.
patent: 5130143 (1992-07-01), Strickland et al.
patent: 5175147 (1992-12-01), Folkman et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5227158 (1993-07-01), Jardieu
patent: 5234908 (1993-08-01), Szabo et al.
patent: 5262298 (1993-11-01), Shipley et al.
patent: 5288704 (1994-02-01), Ungheri et al.
patent: 5314872 (1994-05-01), Kato et al.
patent: 5318890 (1994-06-01), Rosen et al.
patent: 5332671 (1994-07-01), Ferrara et al.
patent: 5389520 (1995-02-01), Tedder et al.
Sato et al. Characterization of Vascular Permeability-Increasing . . . Japan J. Pharmacol. 1986, vol. 41, pp. 163-171.
Barber et al., "Characterization of a chondroitin 4 -sulfate proteoglycan carrier for heparin neutralizing activity (platelet factor 4) released from human blood platelets" Biochemica et Biophysica Acta 286:312-329 (1972).
Barzu et al., "Heparin-Derived Oligosaccharides: Affinity for Acidic Fibroblast Growth Factor and Effect on Its Growth-Promoting Activity for Human Endothelial Cells" J. Cell Phys. 140:538-548 (1989).
Burgess and Maciag, "The Heparin Binding (Fibroblast) Growth Factor Family of Proteins" Annu. Rev. Biochem. 58:576-606 (1989).
Gitay-Goren et al., "The Binding of Vascular Endothelial Growth Factor to Its Receptors Is Dependent on Cell Surface-associated Heparin-like Molecules" Journal of Biological Chemistry 267:6093-6098 (1992).
Handin et al., "Purification and Binding Properties of Human Platelet Factor Four" Journal of Biological Chemistry 251:4273-4283 (1976).
Ishihara et al., "Preparation of Affinity-fractionated, Heparin-derived Oligosaccharides and Their Effects on Selected Biological Activities Mediated by Basic Fibroblast Growth Factor" Journal of Biological Chemistry 268:4675-4683 (1993).
Kim et al., "Kinetic Analysis of In Vivo Receptor-Dependent Binding of Human Epidermal Growth Factor by Rat Tissues" J. Pharm. Sci. 77:200-207 (1988).
Klagsbrun, M., "The Fibroblast Growth Factor Family: Structural and Biological Properties" Prog. Growth Factor Research 1:207-235 (1989).
Kobayashi et al., "Hepatocyte Growth Factor Elevates the Activity Levels of Glycolipid Sulfotransferasses in Renal Cell Carcinoma Cells" European Journal of Biochemistry 219:407-413 (1994).
Kobayashi et al., "Hepatocyte Growth Factor Specifically Binds to Sulfoglycolipids" Journal of Biological Chemistry 269(13):9817-9821 (1994).
Liu et al., "Importance of the Liver in Plasma Clearance of Hepatocyte Growth Factor in Rats" Am. J. Physiol. (Gastrointest. Liver Physiol. 26) 263:G642-G649 (1992).
Loscalzo et al., "The Interaction of Platelet Factor Four and Glycosaminoglycans" Archives of Biochemistry & Biophysics 240:446-455 (1985).
Matsumoto et al., "Heparin as an Inducer of Hepatocyte Growth Factor" J. Biochem. 114:820-826 (1993).
Mizuno et al., "Hairpin loop and second kringle domain are essential sites for heparin binding and biological activity of hepatocyte growth factor" Journal of Biological Chemistry 269(2):1131-1136 (1994).
Moscatelli, David, "Metabolism of Receptor-bound and Matrix-bound Basic Fibroblast Growth Factor by Bovine Capillary Endothelial Cells" Journal of Cell Biology 107:759 (1988).
Mueller et al., "Stabilization by Heparin of Acidic Fibroblast Growth Factor Mitogenicity for Human Endothelial Cells in Vitro" J. Cell. Phys. 140:439-448 (1989).
Naka et al., "Heparin modulates the receptor-binding and mitogenic activity of hepatocyte growth factor on hepatocytes" Exp. Cell Res. 209:317-324 (1993).
Norgard-Sumnicht et al., "Calcium-dependent Heparin-Like Ligands for L-Selectin in Nonlymphoid Endothelial Cells" Science 261:480-483 (1993).
Poschmann et al., "Exchange Transfusion with Heparinished Fresh Blood in Necrotising Enterocolitis" Lancet pp. 824-825 (1979).
Saksela et al., "Endothelial Cell-derived Heparan Sulfate Binds Basic Fibroblast Growth Factor and Protects It From Proteolytic Degradation" J. Cell. Phys. 107:743-751 (1988).
Soker et al., "Vascular Endothelial Growth Factor Is Inactivated by Binding to alpha 2-macroglobulin and the binding is inhibited by heparin" Journal of Biological Chemistry 268(11):7685-7691 (1993).
Sugiyama et al., "Receptor-Mediated Disposition of Polypeptides: Kinetic Analysis of the Transport of Epidermal Growth Factor as a Model Peptide Using in Vitro Isolated Perfused Organs and in Vivo System" J. Controlled Release 13:157-174 (1990).
Sugiyama et al., "Receptor-Mediated Hepatic Clearance of Peptide Hormones" Topics in Pharmaceutical Sciences pp. 429-443 (1989).
Sugiyama et al., "Receptor-Mediated Transport of Peptide Hormones and its Importance in the Overall Hormone Disposition in the Body" Pharm. Res. 6:192-202 (1989).
Talpas et al., "H-NMR Studies of Bovine Platelet Factor 4: Histidine Assignments and Interactions with Heparin" Biochemica et Biophysica Acta 1078:208-218 (1991).
Thomas et al., "Pure Brian-Derived Acidic Fibroblast Growth Factor is a Potent Angiogenic Vascular Endothelial Cell Mitogen with Sequence Homology to Interleukin 1" Proc. Natl. Acad. Sci. 82:6409-6413 (1985).
Tyrell et al., "Structure and Biological Activities of a Heparin-derived Hexasaccharide with High Affinity for Basic Fibroblast Growth Factor" Journal of Biological Chemistry 268:4684-4689 (1993).
Webb et al., "Binding to Heparan Sulfate or Heparin Enhances Neutrophil Responses to Interleukin 8" Proc. Natl. Acad. Sci. 90:7158-7162 (1993).
Yayon et al., "Cell Surface, Herparin-like Molecules Are Required for Binding of Basic Fibroblast Growth Factor to its High Affinity Receptor" Cell 64:841-848 (1991).
Zucker et al., "Immunoregulatory Activity of Peptides Related to Platelet Factor 4" Proc. Natl. Acad. Sci. 86:7571-7574 (1989).
Wilting et al, In vivo effects of vascular endothelial growth factor . . . Cell Tissue Research. vol. 274, pp. 163-172, 1993.
Chamow Steven
Modi Nishit
Schwall Ralph
Zioncheck Thomas
Genentech Inc.
Russel Jeffrey E.
LandOfFree
Method of extending the plasma half-life of vascular endothelial does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of extending the plasma half-life of vascular endothelial, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of extending the plasma half-life of vascular endothelial will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2047719